A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate Efficacy, Safety, and Tolerability of HM15275 for 36 Weeks in Obese or Overweight Subjects Without Diabetes Mellitus
Latest Information Update: 05 Nov 2026
At a glance
- Drugs Zantrutide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Hanmi Pharmaceutical
Most Recent Events
- 23 Oct 2026 According to Hanmi Pharmaceutical media relese, this trial is expected to complete in in the first half of 2027.
- 08 Apr 2026 Status changed from recruiting to active, no longer recruiting.
- 11 Dec 2025 Status changed from not yet recruiting to recruiting.